Sai Parenteral's (BOM:544742) Other Financing: ₹-32 Mil (TTM As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:544742 Sai Parenteral's Ltd BOM:544742
14 GF Score
Price ₹568.95
! 7 Warning Signs
View Full Analysis

What is Sai Parenteral's Other Financing?

Sai Parenteral's BOM:544742 +5.09% 14 Other Financing is ₹-32 Mil as of Sep. 2025. GuruFocus rates BOM:544742 with a GF Score™ of 14/100. The stock has 7 warning signs investors should review.

Sai Parenteral's's Other Financing for the six months ended in Sep. 2025 was ₹-32 Mil.

Sai Parenteral's's Other Financing for the trailing twelve months (TTM) ended in Sep. 2025 was ₹-32 Mil.

Sai Parenteral's Other Financing Historical Data

* Premium members only.

The historical data trend for Sai Parenteral's's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sai Parenteral's Other Financing Chart

Sai Parenteral's Annual Data
Trend Mar23 Mar24 Mar25
Other Financing
-119.85 -111.06 -119.09

Sai Parenteral's Semi-Annual Data
Mar23 Mar24 Mar25 Sep25
Other Financing 0.00 0.00 0.00 -32.07
BOM:544742
14GF Score
Sai Parenteral's Ltd BOM:544742
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sai Parenteral's Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Sep. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₹-32 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of ₹-32 Mil mean?
Sai Parenteral's (BOM:544742) has a Other Financing of ₹-32 Mil as of Sep. 2025. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Sai Parenteral's and its competitors.
Is Sai Parenteral's' Other Financing too high?
Sai Parenteral's' current Other Financing is ₹-32 Mil. Overall, Sai Parenteral's has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Sai Parenteral's' Other Financing compare to LLY and JNJ?
Sai Parenteral's' Other Financing of ₹-32 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Drug Manufacturers company?
A good Other Financing depends on the Drug Manufacturers industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Sai Parenteral's and its competitors. Sai Parenteral's's current Other Financing is ₹-32 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sai Parenteral's stock overvalued right now?
Sai Parenteral's (BOM:544742) has a current Other Financing of ₹-32 Mil. The current Other Financing is ₹-32 Mil. Sai Parenteral's' overall GF Score™ is 14/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Sai Parenteral's (BOM:544742), the current Other Financing is ₹-32 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sai Parenteral's Business Description

Other Exchanges SAIPARENT:India
Address Plot No 39, 5th floor, Lavanya Arcade Jayabheri Enclave, Gachibowli, K.V.Rangareddy, Seri Lingampally, Hyderabad, TG, IND, 500032
Sai Parenteral's Ltd is a diversified pharmaceutical formulations company. Its business is organised in two verticals: (i) Branded Generic Formulations: Through the branded generics portfolio, it serves the domestic market with formulations across multiple therapeutic areas. and (ii) Contract Development and Manufacturing Organisation (CDMO): It provides CDMO services to pharmaceutical companies, supporting activities from product development to commercial manufacturing. Its product portfolio includes cardiovascular care, neuropsychiatry, anti-diabetic therapy, respiratory health, antibiotics, gastroenterology, vitamins, etc. The majority of the company's revenue is derived from the Branded Generic Formulations business.
14GF Score

Get the complete analysis for BOM:544742

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹568.95
Price